CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

August 30, 2021

Study Completion Date

December 30, 2022

Conditions

Refractory Hematologic CancerAllogeneic Stem Cell Transplantation

Interventions

DRUG

CLAGE-FluBu

Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan

Trial Locations (1)

Blood & Marrow Transplantation Center, RuiJin Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT03882203 - CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia | Biotech Hunter | Biotech Hunter